1190 Repurposing FDA-Approved Drugs for Glioblastoma: High-Throughput Screening in Patient-Derived Organoid Models

View at publisher Summarise with VIRAT
Authors: Charles N. de Leeuw, Megan Brunelle, Tiffany Bui, Monika Ashok Davare
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Glioblastoma (GBM) remains one of the most lethal adult brain tumors, with minimal advances in standard-of-care over decades. There is an urgent need for novel therapeutics with rapid translational potential. METHODS: We screened 166 FDA-approved drugs across 12 genomically diverse patient-derived GBM xenograft models cultured under organoid/explant-like conditions. Cells were treated with 10 µM of each drug ± TMZ (IC30), and viability was assessed in quadruplicate. Responses were compared to non-neoplastic human astrocytes, fibroblasts, and neural stem cells using t-tests with FDR correction. Synergistic interactions were evaluated using SynergyFinder. RESULTS: Twenty-eight drugs sensitized GBM cells to TMZ without affecting control cells, with up to 11 sensitizers per patient. While most effects were patient-specific, 11 drugs enhanced TMZ response in ≥2 models. Two drugs of interest affecting subsets of GBM include 5-ALA and glasdegib. Separately, up to 12 drugs per sample showed GBM-selective cytotoxicity (≤50% viability) as monotherapies. Notably, 64% of drugs were toxic to control cells. Three agents—decitabine, raloxifene, and gefitinib—demonstrated selective toxicity in ≥6 GBM models and collectively covered all 12. Consistent with this finding, TCGA data demonstrated elevated expression of DNMT1, ESR2, and EGFR in tumor samples compared to normal tissue. Avapritinib, recently shown effective in PDGFRA-altered pediatric high-grade glioma, significantly reduced viability in several GBM lines. CONCLUSIONS: This is, to our knowledge, the largest screen of FDA-approved drugs in patient-derived GBM models in combination with temozolomide. By incorporating non-neoplastic cell controls, we identified compounds with tumor-selective activity and TMZ sensitization. These findings nominate several candidates—including avapritinib, an agent not previously evaluated in GBM—for rapid clinical translation. Additional in vivo validation in mouse orthotopically injected GBM is pending.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Computational Drug Discovery Methods Cancer Mechanisms and Therapy

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
232–232
Publication date
26 March 2026
Language
EN